WO2001097806A1 - Cox-2 inhibitors and the prevention of the side effects of radiation therapy - Google Patents
Cox-2 inhibitors and the prevention of the side effects of radiation therapy Download PDFInfo
- Publication number
- WO2001097806A1 WO2001097806A1 PCT/US2001/019593 US0119593W WO0197806A1 WO 2001097806 A1 WO2001097806 A1 WO 2001097806A1 US 0119593 W US0119593 W US 0119593W WO 0197806 A1 WO0197806 A1 WO 0197806A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cox
- radiation
- inhibitors
- side effects
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01950340A EP1309328A4 (en) | 2000-06-20 | 2001-06-20 | Cox-2 inhibitors and the prevention of the side effects of radiation therapy |
CA002412362A CA2412362A1 (en) | 2000-06-20 | 2001-06-20 | Cox-2 inhibitors and the prevention of the side effects of radiation therapy |
JP2002503290A JP2003535896A (en) | 2000-06-20 | 2001-06-20 | COX-2 inhibitor and method of preventing side effects of radiation therapy |
MXPA02012879A MXPA02012879A (en) | 2000-06-20 | 2001-06-20 | Cox-2 inhibitors and the prevention of the side effects of radiation therapy. |
AU2001271341A AU2001271341A1 (en) | 2000-06-20 | 2001-06-20 | COX-2 inhibitors and the prevention of the side effects of radiation therapy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21268500P | 2000-06-20 | 2000-06-20 | |
US60/212,685 | 2000-06-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001097806A1 true WO2001097806A1 (en) | 2001-12-27 |
Family
ID=22792051
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/019593 WO2001097806A1 (en) | 2000-06-20 | 2001-06-20 | Cox-2 inhibitors and the prevention of the side effects of radiation therapy |
Country Status (8)
Country | Link |
---|---|
US (1) | US20020035139A1 (en) |
EP (1) | EP1309328A4 (en) |
JP (1) | JP2003535896A (en) |
CN (1) | CN1437470A (en) |
AU (1) | AU2001271341A1 (en) |
CA (1) | CA2412362A1 (en) |
MX (1) | MXPA02012879A (en) |
WO (1) | WO2001097806A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002080927A1 (en) * | 2001-04-05 | 2002-10-17 | Recordati Industria Chimica E Farmaceutica Spa | Use of selective cox-2 inhibitors for the treatment of urinary incontinence |
WO2010017332A2 (en) * | 2008-08-07 | 2010-02-11 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services | Radioprotectants targeting thrombospondin-1 and cd47 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2690188C2 (en) * | 2017-05-26 | 2019-05-31 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | New multitarget preparation for treating diseases in mammals |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6239137B1 (en) * | 1995-07-21 | 2001-05-29 | Savvipharm Inc | Salts of aminoimidazole carboxamide and 5 amino or substituted amino 1,2,3-triazole, induce apoptosis, inhibit DNA synthesis and control cyclooxygenase activity |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5506145A (en) * | 1994-12-02 | 1996-04-09 | Bull; Brian S. | Determination of an individual's inflammation index from whole blood fibrinogen and hematocrit or hemoglobin measurements |
US6486177B2 (en) * | 1995-12-04 | 2002-11-26 | Celgene Corporation | Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate |
US6355656B1 (en) * | 1995-12-04 | 2002-03-12 | Celgene Corporation | Phenidate drug formulations having diminished abuse potential |
US6096728A (en) * | 1996-02-09 | 2000-08-01 | Amgen Inc. | Composition and method for treating inflammatory diseases |
ES2207759T3 (en) * | 1996-12-06 | 2004-06-01 | Amgen Inc. | COMBINATION THERAPY USING A PROTEIN OF UNION OF THE TUMOR NECROSIS FACTOR (TNF) IN THE TREATMENT OF DISEASES Induced by TNF. |
US5770217A (en) * | 1997-07-02 | 1998-06-23 | Atlatl, Inc. | Dietary supplement for hematological, immune and appetite enhancement |
US6025353A (en) * | 1997-11-19 | 2000-02-15 | G.D. Searle & Co. | Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents |
US6297015B1 (en) * | 1998-09-24 | 2001-10-02 | Ira Shafran | Crohn's disease diagnostic and treatment methods and compositions |
US6649645B1 (en) * | 1998-12-23 | 2003-11-18 | Pharmacia Corporation | Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia |
WO2001091856A2 (en) * | 2000-06-01 | 2001-12-06 | Pharmacia Corporation | Use of cox2 inhibitors for treating skin injury from exposure to ultraviolet radiation |
US6306842B1 (en) * | 2000-06-02 | 2001-10-23 | Medinox, Inc. | Protected forms of a combination of pharmacologically active agents and uses therefor |
-
2001
- 2001-06-20 CN CN01811513A patent/CN1437470A/en active Pending
- 2001-06-20 CA CA002412362A patent/CA2412362A1/en not_active Abandoned
- 2001-06-20 AU AU2001271341A patent/AU2001271341A1/en not_active Abandoned
- 2001-06-20 JP JP2002503290A patent/JP2003535896A/en active Pending
- 2001-06-20 US US09/884,466 patent/US20020035139A1/en not_active Abandoned
- 2001-06-20 EP EP01950340A patent/EP1309328A4/en not_active Withdrawn
- 2001-06-20 WO PCT/US2001/019593 patent/WO2001097806A1/en not_active Application Discontinuation
- 2001-06-20 MX MXPA02012879A patent/MXPA02012879A/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6239137B1 (en) * | 1995-07-21 | 2001-05-29 | Savvipharm Inc | Salts of aminoimidazole carboxamide and 5 amino or substituted amino 1,2,3-triazole, induce apoptosis, inhibit DNA synthesis and control cyclooxygenase activity |
Non-Patent Citations (1)
Title |
---|
See also references of EP1309328A4 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002080927A1 (en) * | 2001-04-05 | 2002-10-17 | Recordati Industria Chimica E Farmaceutica Spa | Use of selective cox-2 inhibitors for the treatment of urinary incontinence |
WO2010017332A2 (en) * | 2008-08-07 | 2010-02-11 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services | Radioprotectants targeting thrombospondin-1 and cd47 |
WO2010017332A3 (en) * | 2008-08-07 | 2010-04-15 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services | Radioprotectants targeting thrombospondin-1 and cd47 |
US8951527B2 (en) | 2008-08-07 | 2015-02-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Radioprotectants targeting thrombospondin-1 and CD47 |
Also Published As
Publication number | Publication date |
---|---|
US20020035139A1 (en) | 2002-03-21 |
JP2003535896A (en) | 2003-12-02 |
EP1309328A1 (en) | 2003-05-14 |
CN1437470A (en) | 2003-08-20 |
MXPA02012879A (en) | 2004-07-30 |
CA2412362A1 (en) | 2001-12-27 |
AU2001271341A1 (en) | 2002-01-02 |
EP1309328A4 (en) | 2006-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hour et al. | Curcumin enhances cytotoxicity of chemotherapeutic agents in prostate cancer cells by inducing p21WAF1/CIP1 and C/EBPβ expressions and suppressing NF‐κB activation | |
Brar et al. | Reactive oxygen species from NAD (P) H: quinone oxidoreductase constitutively activate NF-κB in malignant melanoma cells | |
Zhou et al. | A high dose of ionizing radiation induces tissue-specific activation of nuclear factor-κB in vivo | |
US20130316994A1 (en) | Methods of Reducing Risk of Hepatobiliary Dysfunction During Rapid Weight Loss with METAP-2 Inhibitors | |
Jonsson et al. | Mycophenolic acid inhibits inosine 5′-monophosphate dehydrogenase and suppresses production of pro-inflammatory cytokines, nitric oxide, and LDH in macrophages | |
Grimes et al. | Cyclooxygenase-2 inhibitor, nimesulide, improves radiation treatment against non-small cell lung cancer both in vitro and in vivo | |
Wang et al. | Synergistic inhibitory effect of sulforaphane and 5‐fluorouracil in high and low metastasis cell lines of salivary gland adenoid cystic carcinoma | |
Young et al. | Phase I and clinical pharmacologic evaluation of lonidamine in patients with advanced cancer | |
TW201929885A (en) | Inhibition of androgen receptor by extracts of medicinal herbs and compositions thereof | |
AU2004279260B2 (en) | Composition for treatment of osteoarthritis containing apigenin as chondroregenerative agent | |
US20020035139A1 (en) | COX-2 inhibitors and the prevention of the side effects of radiation therapy | |
ROSENBERG | Fulminating adrenocortical hyperfunction associated with islet-cell carcinoma of the pancreas: Case report | |
Berg et al. | A phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinoma | |
Denis et al. | Early clinical experience with liarozole (Liazal™) in patients with progressive prostate cancer | |
KR20040066886A (en) | Use of anastrozole for the treatment of post-menopausal women having early breast cancer | |
Kim et al. | Overexpression of cyclooxygenase-2 in childhood ependymomas: role of COX-2 inhibitor in growth and multi-drug resistance in vitro | |
TW202029961A (en) | Use of ar antagonist combined with parp inhibitor in preparation of medicament for treating prostate cancer | |
Singh et al. | A DISCUSSION ON CHEMOPREVENTION OF ORAL CANCER BY SELECTIVE CYCLOOXYGENASE-2 (COX-2) INHIBITORS. | |
CN111166756B (en) | 20 Use of (S) -ginsenoside-Rg 3 in reversing drug resistance of glioma cells to chemotherapeutic drugs | |
Hacioglu | Capsaicin Enhances Temozolomide-Resistant Glioblastoma Cells’ Chemosensitivity and Ferroptosis through FHOD1/IRF2 Downregulation | |
Bulbul et al. | The effect of nitrofurantoin on bladder tumor cell lines: in vitro growth and implantation in the cauterized mouse bladder | |
WO2022253748A1 (en) | Combinations for the treatment of hpv | |
CN116492325A (en) | Drug development for inhibiting Tet target protein by taking itaconic acid as starting point | |
Petrylak | Chemotherapy for the treatment of hormone-refractory prostate cancer: evaluating new targets based on apoptotic pathways | |
US20050107352A1 (en) | Method of treating benign prostatic hyperplasia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2412362 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/012879 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2002 503290 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018115136 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001950340 Country of ref document: EP Ref document number: 2001271341 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2001950340 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001950340 Country of ref document: EP |